Alimera Sciences Inc. - notizie pubblicate 237 - letture 2.923
ALIMERA SCIENCES INC.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Morphic Holding, Inc. (Nasdaq MORF), Desktop Metal, Inc. (NYSE DM), Alimera Sciences, Inc. (Nasdaq ALIM), Avangrid, Inc. (NYSE AGR)
Bala cynwyd, pa., july 08, 2024 (globe newswire) -- brodsky & smith reminds investors of the following investigations. if you own shares and wish to discuss the investigation, ...
ALIMERA SCIENCES INC.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alimera Sciences, Inc. (Nasdaq ALIM), Avangrid, Inc. (NYSE AGR), PlayAGS, Incorporated (NYSE AGS), RBAZ Bancorp, Inc. (OTCPK RBAZ)
Bala cynwyd, pa., july 01, 2024 (globe newswire) -- brodsky & smith reminds investors of the following investigations. if you own shares and wish to discuss the investigation, ...
ALIMERA SCIENCES INC.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alimera Sciences, Inc. (Nasdaq ALIM), Avangrid, Inc. (NYSE AGR), SilverBow Resources, Inc. (NYSE SBOW), Reneo Pharmaceuticals, Inc. (Nasdaq RPHM)
Bala cynwyd, pa., june 25, 2024 (globe newswire) -- brodsky & smith reminds investors of the following investigations. if you own shares and wish to discuss the investigation, ...
ALIMERA SCIENCES INC.
Material Agreement Form 8 K
Item 1.01. entry into a material definitive agreement. on june 19, 2024, alimera sciences, inc. (the "company") entered into a letter agreement (the "letter agreemen ...
ALIMERA SCIENCES INC.
ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences - Form 425
Ani pharmaceuticals to further expand rare disease business through acquisition of alimera sciences conference call scheduled for today at 8:30 a.m. et · strengthens rare disease ...
ALIMERA SCIENCES INC.
ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences Form 8 K
Ani pharmaceuticals to further expand rare disease business through acquisition of alimera sciences conference call scheduled for today at 8:30 a.m. et · strengthens rare disease ...
ALIMERA SCIENCES INC.
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atlanta, june 04, 2024 (globe newswire) -- alimera sciences, inc. (nasdaq: alim) ("alimera" or the "company"), a global pharmaceutical company whose mission is ...
ALIMERA SCIENCES INC.
Quarterly Report for Quarter Ending March 31, 2024 (Form 10-Q)
Alim-20240331x10q table of contents united states securities and exchange commission washington, d.c. 20549 form 10-q (mark one) x quarterly report pursuant to section 13 or 15(d) ...
ALIMERA SCIENCES INC.
Alimera Sciences Reports First Quarter 2024 Results - Form 8-K
Alimera sciences reports first quarter 2024 results · net revenue up 70% to $23million vs. q1 2023 · global end user demand up 23% vs. q1 2023 · reiterates improved 2024 net ...
ALIMERA SCIENCES INC.
Alimera Sciences Reports First Quarter 2024 Results
Net revenue up 70% to $23 million vs. q1 2023 global end user demand up 23% vs. q1 2023 reiterates improved 2024 net revenue and adjusted ebitda guidance atlanta, may 14, 2024 (glo ...
ALIMERA SCIENCES INC.
Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences
Atlanta, may 07, 2024 (globe newswire) -- alimera sciences, inc. (nasdaq: alim) ("alimera"), a global pharmaceutical company whose mission is to be invaluable to patients ...
ALIMERA SCIENCES INC.
Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update
Atlanta, april 30, 2024 (globe newswire) -- alimera sciences, inc. (nasdaq: alim) (alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicia ...
ALIMERA SCIENCES INC.
Amendment to Annual Report - Form 10-K/A
Alim-20231231x10ka united states securities and exchange commission washington, d.c. 20549 form 10-k/a (amendment no. 1) (mark one) annual report pursuant to section 13 or 15(d ...
ALIMERA SCIENCES INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ALIMERA SCIENCES INC.
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atlanta, march 20, 2024 (globe newswire) -- alimera sciences, inc. (nasdaq: alim) ("alimera" or the "company"), a global pharmaceutical company whose mission is ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti